Emerging therapies in Parkinson disease - repurposed drugs and new approaches.

ABSTRACT: Parkinson disease (PD) treatment options have conventionally focused on dopamine replacement and provision of symptomatic relief. Current treatments cause undesirable adverse effects, and a large unmet clinical need remains for treatments that offer disease modification and that address symptoms resistant to levodopa. Advances in high-throughput drug screening methods for small molecules, developments in disease modelling and improvements in analytical technologies have collectively contributed to the emergence of novel compounds, repurposed drugs and new technologies. In this Review, we focus on disease-modifying and symptomatic therapies under development for PD. We review cellular therapies and repurposed drugs, such as nilotinib, inosine, isradipine, iron chelators and anti-inflammator

SUBMITTER: Elkouzi A 

PROVIDER: S-EPMC7758837 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature